PMID- 28344859
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210112
IS  - 2162-4011 (Print)
IS  - 2162-402X (Electronic)
IS  - 2162-4011 (Linking)
VI  - 6
IP  - 2
DP  - 2017
TI  - HLA class II antigen-processing pathway in tumors: Molecular defects and clinical 
      relevance.
PG  - e1171447
LID - 10.1080/2162402X.2016.1171447 [doi]
LID - e1171447
AB  - The human leukocyte antigen (HLA) class II antigen-processing machinery (APM) 
      presents to cognate CD4(+) T-cells antigenic peptides mainly generated from 
      exogeneous proteins in the endocytic compartment. These CD4(+) T cells exert 
      helper function, but may also act as effector cells, thereby recognizing HLA 
      class II antigen-expressing tumor cells. Thus, HLA class II antigen expression by 
      tumor cells influences the tumor antigen (TA)-specific immune responses and, 
      depending on the cancer type, the clinical course of the disease. Many types of 
      human cancers express HLA class II antigens, although with marked differences in 
      their frequency. Some types of cancer lack HLA class II antigen expression, which 
      could be due to structural defects or deregulation affecting different components 
      of the complex HLA class II APM and/or from lack of cytokine(s) in the tumor 
      microenvironment. In this review, we have summarized the information about HLA 
      class II antigen distribution in normal tissues, the structural organization of 
      the HLA class II APM, their expression and regulation in malignant cells, the 
      defects, which have been identified in malignant cells, and their functional and 
      clinical relevance.
FAU - Seliger, Barbara
AU  - Seliger B
AD  - Martin Luther-University Halle-Wittenberg, Institute of Medical Immunology , 
      Halle, Germany.
FAU - Kloor, Matthias
AU  - Kloor M
AD  - Department of Applied Tumor Biology, Institute of Pathology, University Hospital 
      Heidelberg, Clinical Cooperation Unit Applied Tumor Biology, DKFZ (German Cancer 
      Research Center) , Heidelberg, Germany.
FAU - Ferrone, Soldano
AU  - Ferrone S
AD  - Departments of Surgery and Orthopedic Surgery, Massachusetts General Hospital, 
      Harvard Medical School , Boston, MA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20170206
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
PMC - PMC5353941
OTO - NOTNLM
OT  - Antigen-processing
OT  - HLA class II
OT  - immune response, tumor
EDAT- 2017/03/28 06:00
MHDA- 2017/03/28 06:01
PMCR- 2018/02/06
CRDT- 2017/03/28 06:00
PHST- 2016/02/18 00:00 [received]
PHST- 2016/03/21 00:00 [revised]
PHST- 2016/03/23 00:00 [accepted]
PHST- 2017/03/28 06:00 [entrez]
PHST- 2017/03/28 06:00 [pubmed]
PHST- 2017/03/28 06:01 [medline]
PHST- 2018/02/06 00:00 [pmc-release]
AID - 1171447 [pii]
AID - 10.1080/2162402X.2016.1171447 [doi]
PST - epublish
SO  - Oncoimmunology. 2017 Feb 6;6(2):e1171447. doi: 10.1080/2162402X.2016.1171447. 
      eCollection 2017.